Bio-Techne
Price: 52.50Company and Business Model
Bio-Techne Corporation operates in the healthcare sector, specializing in the development and manufacturing of biotechnology products and tools. Its core offerings include proteins, antibodies, and reagents used in research and clinical applications. Major business segments consist of Protein Sciences, Diagnostics, and Clinical Diagnostics, with primary revenue sources stemming from sales of research reagents and instruments. The company serves academic, pharmaceutical, and biotechnology markets.
Investment Profile
The investment profile of Bio-Techne is more aligned with balanced investors, given its moderate growth potential and dividend yield. The stock exhibits characteristics suitable for those seeking a mix of capital appreciation and income, though it carries a higher risk profile. Investors may consider a medium to long-term horizon for potential returns, while liquidity remains moderate.
Fundamental metrics (experimental)
- EPS (TTM) — earnings per share for the last 12 months, $
- 0.71 OK
- Revenue QoQ — quarter-over-quarter revenue growth
- 5.3% ↑
- EPS surprise
- -3.6% in line
- 20d volatility
- 2.8% stable
- Dividend yield
- 0.6% low last ex-date: 2026-05-18
Track in portfolio
Price chart
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-06-05 02:49 | Sell | Hold | Mixed performance; cautious outlook due to volatility. |
| 2026-05-30 02:52 | Hold | Sell | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-08 15:11 | — | Hold | Weak fundamentals and negative momentum raise significant concerns. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-05-14 20:21 | RBC Capital | Update | — → 62 | 44.74 |
| 2026-05-07 12:07 | Evercore ISI | Target Lowered | 54 → 50 | 49.265 |
| 2026-05-07 11:26 | Stifel Nicolaus | Target Lowered | 65 → 50 | 47.405 |
Nothing yet